Member Info for Laura2022

When you're losing £6mln a year 2024 then £4.5mln 2025 its going to be reflected in the placing needs

However

Can buy at 1.05p so have taken a few as the RNS seems to indicate some positivity

I will trust the RNS and my own due diligence thanks

Buying last year is proving valuable

And dividend to come

Boldocus

With funding and imminent gold production what would make it drop ??

Can't see any reason

I bought a load this week

Thanks

Jennimgs still at over 22%

Another £170,000 bought

RC Fornax (AIM: RCFX), the UK-based consultancy delivering outcome-based engineering solutions to the defence sector's most critical platforms - accredited, in-demand, and built to scale, is pleased to announce that it has been unconditionally accepted by Aurora Engineering Partnership ("Aurora") as a Specialist Provider on Evolve, its Engineering Delivery Partnership ("EDP") Provider Network, a major UK defence engineering framework.

Nick Tulloch, ECR's Chairman, commented: "Today's £1.5 million Fundraising is a major step forward for ECR and we are delighted by the backing received from institutional investors. This support reflects confidence in both our strategy and our progress as we establish ECR as a multi-site gold company.

"Our immediate focus is on near-term production. At the Raglan Project, with an operating team now secured, the Board expects initial gold this month.

Thanks Chesh

From my simple observations it looks like ECR is on the cusp of a major re rate

Welcome back after more than 2 months Debull

Chesh

I appreciate its difficult as apples and pears but now might ECR at £10mln with its JORC compare to for example AAZ PAF etc

3 ton4 times over 2yrs ECR has nearly got past 0 32-0.35

With gold and silver flying and production imminent the current cap £8mln market value seems ludicrously cheap?

Possibly the best placed cheapest soon to be producer

I've bought this week

Was never confirmed by SPI ( see original Sky News)

But was a deadline for initial expressions of interest

Watch this space

I'm in at a great average so totally relaxed , unlike some strange accounts

Wadagora

I filtered this user 18mths+ ago

This person has done same on CPI SSPG PYC etc for years

Whata sad life

French based large cap announced

As one of PYC major clients might they invest in PYC ?

Servier Ventures to invest €200 million in biotech and technological companies advancing cutting-edge therapeutic approaches to support innovation primarily across Europe.The creation of this fully owned fund supports Servier’s strategy to strengthen early access to innovation in the Group’s key therapeutic areas of oncology and neurology.

Suresnes (France), January 8, 2026 – Servier, an independent international pharmaceutical company governed by a Foundation, announces the creation of Servier Ventures, a fully owned corporate venture fund. The fund is committed to investing an initial amount of €200 million in innovative biotech and technological companies.

Trets

Good morning

Great to see

TRLS had good backing and todaya announcement has been great for them , its now £2.7mln cap , loses $440k a month and had total revenues of just $370k last year

Shows how undervalued PYC is at £0.85mln cap with £850k revenues

Other bio tech peer valuations

APTA £35mln cap and £1.2mln full year revs( = x 30 annual rev)

FAB £17 mln and £1.96mln full year  and recently reported reduced  revenues for H1 ( x 9)

Some commentary has suggested 100p for FAB which puts its at x90

PYC £0.85mln  and £0.85mln full year which was 40% growth ( x 1)

GENI (£10mln) revenues £1.6mln, losses £2.4

Auto spell

Bio tech

Nai

Most violent techs valued x 10 to x 20 annual revenues, all of them on AIM

PYC despite growing revenues by 30% last year still only valued at x 1 last years income

[  ] Key market drivers

* model informed discovery/bio stats help

> costs $2.5bln and 10-15yrs to get drug to market and less than 5% success rate - PYC modelling drastically cuts this and using MMID/BS can

1) save $100-500mln

2) increase to 20-30% success at Phase II

3) 30-50% fewer patients

[  ] Key growth/CAGR markets which PYC operate

MMID 18% CAGR with market set to be $13bln

Bio Statistics  24% CAGR $40bln market

Regulatory authorities across the world require robust biometrics practices to approve new drugs. Biometrics typically incorporates three main areas:

1. Biostatistics: Supporting the design of clinical studies and analysis of resulting data

2. Statistical Programming: Use of programming language to process, analyse and visualise clinical data

3. Data Management: Setup and oversight of the collection, entry, and validation of clinical trial data

Personalised medicine 7.5% CAGR and largest market is North America ( partner DoseMeRx based there)

You

Clearly have an agemda and amnesia after predominantly being on RCFX for last 3mths

Laura2022

Posts: 15,138

Price: 0.275

No Opinion

Lsegard19 Jan 2026 11:41

Morning

Please seen annual report etc from Sept where accounts were signed off

Cash (+ trade receivables post year end) + grants = c £800,000  , annual report signed accounts till 2026)

* record revenues for year ended June 2025

* record order book

* Recently  booked a further amount of revenues for contracts to be completed Dec 2025

*recently awarded options at 40:, 170% and 350% premiums to current share price , with focus on next step for company of "cash generation "

Key growth in all areas , particularly bio statistics, company very pleased and very confident about the niche growth markets many of which are now mandatory under EU law and most could well become mandatory for drug design. Positive regulatory environment eg FDA